Profiling the Prognosis of Gastric Cancer Patients: Is It Worth Correlating the Survival with the Clinical/Pathological and Molecular Features of Gastric Cancers?

Abstract

Background. The prognosis of gastric cancer patients still remains poor. The aim of this study was investigating the prognostic value of several clinical/pathological/molecular features in a consecutive series of gastric cancers. Methods. 150 R0 gastrectomies plus 77 gastric cancer patients evaluated for the HER2 overexpression were selected. Survival was calculated and patients stratified according to the stage, the T-stage, the LNRs, the LNH, and the HER2 scoring system. ROC curves were calculated in order to compare the performance of the LRN and LNH systems. Results. Prognosis correlated with the stage and with the T-stage. We documented a statistical correlation between the LNRs and the survival. Conversely, a LNH > 15 did not correlate with the outcomes. The ROC curves documented a significant performance of the LRN system, whereas a statistical correlation was documented for the LNH exclusively with the endpoint of disease-free survival. We documented a trend of worse prognosis for patients with an HER2 overexpression, even though it was not of statistical value. Conclusion. The LNR and the evaluation of the HER2 overexpression might be useful since they correlate with survival, might identify patients with a higher risk of recurrence, and might select patients for a tailored medical treatment.

Down‐regulated miRs specifically correlate with non‐cardial gastric cancers and Lauren's classification system

“…Of note, however, standard pathological factors including advanced Stages, LNR categories and a LNH <15 were confirmed as the significant independent variables associated with a worse prognosis, also in line with our previous works and those reported by others …”

“…Interestingly, HER2/Neu receptor was previously reported as a possible target of miR375 using dual luciferase assays and Western blot analysis . On this basis, we reviewed a subset of patients ( n 28) from a previously published series aimed to HER2 over‐expression in gastric cancers in relation to miR375 signature. Interestingly, we could not document significant differences between the rate of HER2/Neu over‐expression (>2 +) in gastric cancers presenting with very low‐ versus higher miR375 expression (respectively 20.8% vs 25.0%, Chi square 0.63), Supplement Fig.…”

Lymph-Node Ratio Classification Strongly Correlates with Cancer Survivals of Patients Who Underwent R0 Resection for Gastric Cancer with More than 15 Nodes Harvested

“…We reported significant values for the disease-free and disease-specific survivals (>0.7) and a borderline significance for the overall survival (AUC 0.69). Our previous paper in this field has been implemented for a comparison of the clinical/pathological features and outcomes of the different LNR subgroups [15]. Indeed, since the LNR subgroup stratification correlated with (a) the stage of the disease, (b) the rate of patients presenting with a relapse and (c) the cancer-related survivals in our analysis, we speculate that this system could implement the current nodal staging criteria and might be of use in identifying patients with a higher risk of recurrence who benefit from an intensive follow-up.…”

“…The enrollment criteria and part of the demographic data of this case series have been previously described [15]. Briefly, this study has been designed as a retrospective analysis of prospectively collected data: the records were thus retrieved and reviewed for the data analysis.…”

Ultrasound and Transcriptomics Identify a Differential Impact of Cisplatin and Histone Deacetylation on Tumor Structure and Microenvironment in a Patient-Derived In Vivo Model of Gastric Cancer

“…Gastric cancer is the fifth most common cancer, and the third, in terms of mortality, worldwide, with a 5-year overall survival rate of 36% for operable cancers; this drops to 5–20% in locally-advanced/metastatic cancers, with a median survival of less than one year [ 1 , 2 ]. This highlights the need for progress in diagnosing and treating gastric cancer.…”